Growth Metrics

West Pharmaceutical Services (WST) Total Non-Current Liabilities (2016 - 2026)

West Pharmaceutical Services has reported Total Non-Current Liabilities over the past 18 years, most recently at $1.0 billion for Q1 2026.

  • Quarterly Total Non-Current Liabilities rose 18.68% to $1.0 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.0 billion through Mar 2026, up 18.68% year-over-year, with the annual reading at $1.0 billion for FY2025, 13.34% up from the prior year.
  • Total Non-Current Liabilities was $1.0 billion for Q1 2026 at West Pharmaceutical Services, up from $1.0 billion in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $1.0 billion in Q1 2026 and troughed at $812.1 million in Q3 2022.
  • The 5-year median for Total Non-Current Liabilities is $890.0 million (2023), against an average of $901.6 million.
  • Biggest five-year swings in Total Non-Current Liabilities: decreased 11.0% in 2022 and later grew 18.68% in 2026.
  • Tracing WST's Total Non-Current Liabilities over 5 years: stood at $880.3 million in 2022, then rose by 1.1% to $890.0 million in 2023, then increased by 1.0% to $898.9 million in 2024, then increased by 13.34% to $1.0 billion in 2025, then rose by 1.28% to $1.0 billion in 2026.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $1.0 billion, $1.0 billion, and $979.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.